We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Sublocade (buprenorphine extended-release) 300 mg/1.5 mL Injection (USA)
Section 19A approved medicine
(Approval lapsed) Sublocade (buprenorphine extended-release) 300 mg/1.5 mL Injection (USA)
Section 19A approval holder
Indivior Pty Ltd ABN 22 169 280 102
Phone
02 9025 0200
Approved until
Status
Expired
Medicines in short supply/unavailable
SUBLOCADE (buprenorphine modified-release) 300 mg/1.5 mL Injection AUST R 303753
Indication(s)
SUBLOCADE is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.